We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00308139
First Posted: March 29, 2006
Last Update Posted: August 26, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
Results First Submitted: February 14, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide, long acting release
Drug: exenatide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Exenatide Once Weekly -> Exenatide Once Weekly Subcutaneous injection of 2 mg exenatide, once a week.
Exenatide Twice Daily -> Exenatide Once Weekly Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 26 weeks) followed by 2 mg exenatide, once a week.

Participant Flow:   Overall Study
    Exenatide Once Weekly -> Exenatide Once Weekly   Exenatide Twice Daily -> Exenatide Once Weekly
STARTED   152   151 
Intent to Treat (ITT)   148 [1]   147 [1] 
ITT in the 30-Week Assessment   148 [2]   145 [2] 
Pharmacokinetics Population   129   0 
Evaluable Meal Tolerance Cohort   27   24 
30-Week Completed   128 [3]   130 [3] 
COMPLETED   58 [4]   64 [4] 
NOT COMPLETED   94   87 
Adverse Event                20                14 
Lost to Follow-up                13                8 
Protocol Violation                3                2 
Withdrawal of Consent                40                42 
Investigator Decision                11                10 
Loss of Glucose Control                5                7 
Administrative                1                4 
Other                1                0 
[1] Subjects who received at least one injection of lead-in exenatide 5 mcg.
[2] ITT Subjects who received at least one injection of randomized dose.
[3] Subjects who completed 30 weeks of assessment
[4] Subjects who completed 364 weeks of assessment



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Exenatide Once Weekly -> Exenatide Once Weekly Subcutaneous injection of 2 mg exenatide, once a week.
Exenatide Twice Daily -> Exenatide Once Weekly Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 26 weeks) followed by 2 mg exenatide, once a week.
Total Total of all reporting groups

Baseline Measures
   Exenatide Once Weekly -> Exenatide Once Weekly   Exenatide Twice Daily -> Exenatide Once Weekly   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 148   147   295 
Age 
[Units: Participants]
 		     
<=18 years   0   0   0 
Between 18 and 65 years   122   123   245 
>=65 years   26   24   50 
Age 
[Units: Years]
Mean (Standard Deviation) 		 55.2  (9.72)   54.9  (9.63)   55.0  (9.66) 
Gender 
[Units: Participants]
 		     
Female   66   72   138 
Male   82   75   157 
Glycosylated hemoglobin (HbA1c) 
[Units: Percentage of total hemoglobin]
Mean (Standard Deviation) 		 8.3  (0.99)   8.3  (1.00)   8.3  (0.99) 
Weight 
[Units: Kg]
Mean (Standard Deviation) 		 101.7  (18.76)   101.9  (21.05)   101.8  (19.90) 
Background Oral Antidiabetic Agent 
[Units: Participants]
 		     
Diet and Exercise   21   22   43 
Metformin (MET)   56   50   106 
Sulfonylurea (SU)   6   10   16 
Thiazolidinediones (TZD)   2   7   9 
MET+SU   43   39   82 
MET+TZD   14   14   28 
SU+TZD   5   5   10 
SU+MET+TZD   1   0   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in HbA1c From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 1

2.  Secondary:   Change in HbA1c From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 2

3.  Secondary:   Percentage of Subjects Achieving HbA1c Target of <7%   [ Time Frame: Week 30 ]
  Show Outcome Measure 3

4.  Secondary:   Percentage of Subjects Achieving HbA1c Target of <7%   [ Time Frame: Week 364 ]
  Show Outcome Measure 4

5.  Secondary:   Percentage of Subjects Achieving HbA1c Target of <=6.5%   [ Time Frame: Week 30 ]
  Show Outcome Measure 5

6.  Secondary:   Percentage of Subjects Achieving HbA1c Target of <=6.5%   [ Time Frame: Week 364 ]
  Show Outcome Measure 6

7.  Secondary:   Percentage of Subjects Achieving HbA1c Target of <=6.0%   [ Time Frame: Week 30 ]
  Show Outcome Measure 7

8.  Secondary:   Exenatide LAR Steady State Concentration From Week 29 to Week 30   [ Time Frame: Week 29 to Week 30 ]
  Show Outcome Measure 8

9.  Secondary:   Change in 2 Hours (2h) Postprandial Glucose From Baseline to Week 14   [ Time Frame: Day -3, Week 14 ]
  Show Outcome Measure 9

10.  Secondary:   Change in Body Weight From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 10

11.  Secondary:   Change in Body Weight From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 11

12.  Secondary:   Change in Fasting Plasma Glucose From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 12

13.  Secondary:   Change in Fasting Plasma Glucose From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Hide Outcome Measure 13

Measure Type Secondary
Measure Title Change in Fasting Plasma Glucose From Baseline to Week 364
Measure Description Change in fasting plasma glucose from baseline (Day -3) to Week 364.
Time Frame Day -3, Week 364  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
7-Year Completer Population. Missing data up to Week 364 were imputed using the LOCF approach for subjects who had data for at least one scheduled visit (including Early Termination) subsequent to the baseline measurement.

Reporting Groups
  Description
Exenatide Once Weekly -> Exenatide Once Weekly Subcutaneous injection of 2 mg exenatide, once a week.
Exenatide Twice Daily -> Exenatide Once Weekly Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 26 weeks) followed by 2 mg exenatide, once a week.
All Treatment No text entered.

Measured Values
   Exenatide Once Weekly -> Exenatide Once Weekly   Exenatide Twice Daily -> Exenatide Once Weekly   All Treatment 
Participants Analyzed 
[Units: Participants]
 		 58   64   122 
Change in Fasting Plasma Glucose From Baseline to Week 364 
[Units: mg/dL]
Least Squares Mean (95% Confidence Interval) 		 -18.3 
 (-30.8 to -5.7)  		 -27.7 
 (-39.0 to -16.4)  		 -23.6 
 (-33.0 to -14.2) 

No statistical analysis provided for Change in Fasting Plasma Glucose From Baseline to Week 364



14.  Secondary:   Change in Blood Pressure From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 14

15.  Secondary:   Change in Blood Pressure From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 15

16.  Secondary:   Change in Total Cholesterol From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 16

17.  Secondary:   Change in Total Cholesterol From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 17

18.  Secondary:   Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 30   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 18

19.  Secondary:   Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 19

20.  Secondary:   Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 364   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 20

21.  Secondary:   Ratio of Triglycerides at Week 30 to Baseline   [ Time Frame: Day -3, Week 30 ]
  Show Outcome Measure 21

22.  Secondary:   Ratio of Triglycerides at Week 364 to Baseline   [ Time Frame: Day -3, Week 364 ]
  Show Outcome Measure 22

23.  Secondary:   Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With SU Use at Screening   [ Time Frame: Day 1 to Week 364 ]
  Show Outcome Measure 23

24.  Secondary:   Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening   [ Time Frame: Day 1 to Week 364 ]
  Show Outcome Measure 24

25.  Primary:   Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)   [ Time Frame: Week 22 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

26.  Secondary:   Sub-study Safety and Tolerability of Exenatide When Administered Using the Once Weekly Single Dose Tray and the Once Weekly Dual (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)   [ Time Frame: Week 22 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Show More Information